Relevance of sentinel lymph node procedure for patients with high-risk endometrial cancer

Gynecologic Oncology

Volumn 136, Issue 1, 2015, Pages 60-64

  Naoura, Iptissem ^a   Canlorbe, Geoffroy ^b   Bendifallah, Sofiane ^a,b   Ballester, Marcos ^a   Daraï, Emile ^a,b  

^a HÔPITAL TENON   (France)

^b INSERM   (France)

Author keywords

Detection rate; Endometrial cancer; ESMO group risk; False negative rate; High risk group; Sentinel lymph node biopsy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; EARLY CANCER; ENDOMETRIUM CANCER; FALSE NEGATIVE RESULT; FEMALE; HIGH RISK PATIENT; HIGH RISK POPULATION; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHOVASCULAR SPACE INVASION; MAJOR CLINICAL STUDY; MICROMETASTASIS; MULTICENTER STUDY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; TUMOR INVASION; VERY ELDERLY; ALGORITHM; CLINICAL TRIAL; ENDOMETRIUM TUMOR; LYMPH NODE; MIDDLE AGED; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY;

EID: 84925228957     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.10.027     Document Type: Article

References (27)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin Févr,2012;62(1):10-29.
2. Kitchener H, Swart AMC, Qian Q, Amos C, Parmar MKB. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet Janv, 2009;373(9658):125-36.
3. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 3 déc 2008;100(23):1707-16.
4. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2010;1 [CD007585].
5. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. J Eur Soc Med Oncol sept 2011;22(Suppl. 6):vi35-9.
6. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 3 avr 2010;375(9721):1165-72.
7. Kumar S, Podratz KC, Bakkum-Gamez JN, Dowdy SC, Weaver AL, McGree ME, et al. Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. Gynecol Oncol janv 2014;132(1):38-43.
8. Achouri A, Huchon C, Bats AS, Bensaid C, Nos C, Lécuru F. Complications of lymphadenectomy for gynecologic cancer. Eur J Surg Oncol janv 2013;39(1):81-6.
9. Ballester M, Dubernard G, Lécuru F, Heitz D, Mathevet P, Marret H, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol mai 2011;12(5):469-76.
10. Khoury-Collado F, Murray MP, Hensley ML, Sonoda Y, Alektiar KM, Levine DA, et al. Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. Gynecol Oncol août 2011;122(2):251-4.
11. Khoury-Collado F, Abu-Rustum NR. Lymphatic mapping in endometrial cancer: a literature review of current techniques and results. J Int Gynecol Cancer Soc déc 2008;18(6):1163-8.
12. Frumovitz M, Bodurka DC, Broaddus RR, Coleman RL, Sood AK, Gershenson DM, et al. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol janv 2007;104(1):100-3.
13. Querleu D, Planchamp F, Narducci F, Morice P, Joly F, Genestie C, et al. Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d'Oncologie Gynécologique. J Int Gynecol Cancer Soc juill 2011;21(5):945-50.
14. Delpech Y, Cortez A, Coutant C, Callard P, Uzan S, Darai E, et al. The sentinel node concept in endometrial cancer: histopathologic validation by serial section and immunohistochemistry. J Eur Soc Med Oncol ESMO nov 2007;18(11):1799-803.
15. Bézu C, Coutant C, Ballester M, Feron J-G, Rouzier R, Uzan S, et al. Ultrastaging of lymph node in uterine cancers. J Exp Clin Cancer Res CR 2010;29:5.
16. Marchiolé P, Buénerd A, Benchaib M, Nezhat K, Dargent D, Mathevet P. Clinical significance of lympho vascular space involvement and lymph node micrometastases in early-stage cervical cancer: a retrospective case-control surgico-pathological study. Gynecol Oncol juin 2005;97(3):727-32.
17. Kang S, Yoo HJ, Hwang JH, Lim M-C, Seo S-S, Park S-Y. Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies. Gynecol Oncol déc 2011;123(3):522-7.
18. Barlin JN, Khoury-Collado F, Kim CH, Leitao Jr MM, Chi DS, Sonoda Y, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol juin 2012;125(3):531-5.
19. Abu-Rustum NR, Gomez JD, Alektiar KM, Soslow RA, Hensley ML, Leitao Jr MM, et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol Nov, 2009;115(2):236-8.
20. Werner HMJ, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, Engh ME, et al. A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis. Eur J Cancer Oxf Engl févr 2013;49(3):625-32.
21. Karateke A, Tug N, Cam C, Selcuk S, Asoglu MR, Cakir S. Discrepancy of pre- and postoperative grades of patients with endometrial carcinoma. Eur J Gynaecol Oncol 2011;32(3):283-5.
22. Frumovitz M, Singh DK, Meyer L, Smith DH, Wertheim I, Resnik E, et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol Déc, 2004;95(3):463-8.
23. 18F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma. Eur J Nucl Med Mol Imaging janv 2011;38(1):74-80.
24. Walentowicz-Sadlecka M, Malkowski B, Walentowicz P, Sadlecki P, Marszalek A, Pietrzak T, et al. The preoperative maximum standardized uptake value measured by 18F-FDG PET/CT as an independent prognostic factor of overall survival in endometrial cancer patients. Int J Biomed Res 2014;2014:234813.
25. Aristizabal P, Graesslin O, Barranger E, Clavel-Chapelon F, Haddad B, Luton D, et al. A suggested modification to FIGO stage I endometrial cancer. Gynecol Oncol mai 2014;133(2):192-6.
26. Bendifallah S, Genin AS, Naoura I, Chabbert Buffet N, Clavel Chapelon F, Haddad B, et al. A nomogram for predicting lymph node metastasis of presumed stage I and II endometrial cancer. Am J Obstet Gynecol sept 2012;207(3):197-8.
27. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang Y-B, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol Off J Am Soc Clin Oncol 10 juill,2013;31(20):2607-18.